Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592176 · ClinicalTrials.gov registry record · Phase 2
The Effect of Bevacizumab (Avastin) on Pterygium
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00592176 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants.
The verdict
NCT00592176, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.
Interventions
- DRUG local injection of bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592176
The ClinicalTrials.gov registry entry for NCT00592176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which local injection of bevacizumab is the first listed.
NCT00592176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00592176 about?
NCT00592176 is a clinical study titled "The Effect of Bevacizumab (Avastin) on Pterygium". The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality o...
What is the current status of trial NCT00592176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2007-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00592176?
The interventions under investigation include: local injection of bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00592176?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.